Related Experiment Video
Updated: Jul 4, 2026
05:38
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy
A H Rajrut1, R J Uitti, M E Fenton
1Division of Neurology, University of Saskatchewan, Saskatchewan, Canada.
Parkinsonism & Related Disorders
|July 2, 2008
Summary
Amantadine (Amd) offers potential benefits for Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA) patients who typically respond poorly to other treatments. This study suggests considering Amd for managing these challenging neurodegenerative conditions.
Area of Science:
- Neurology
- Neuropharmacology
Background:
- Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA) are neurodegenerative diseases with limited treatment options.
- Conventional anti-parkinsonian drugs often show poor efficacy in PSP and MSA patients.
Purpose of the Study:
- To evaluate the therapeutic response of Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA) cases to amantadine (Amd).
- To assess the safety and efficacy of amantadine in managing symptoms of PSP and MSA.
Main Methods:
- Retrospective analysis of 13 Multiple System Atrophy (MSA) and 14 Progressive Supranuclear Palsy (PSP) cases treated between 1970 and 1996.
- Administration of amantadine (Amd) at 100 mg twice daily.
Main Results:
- Amantadine (Amd) showed improvement in 61.5% of MSA cases and 42.9% of PSP cases.
- Adverse effects were reported in 23.1% of MSA patients and 28.6% of PSP patients.
- The NMDA antagonist properties of amantadine are hypothesized to contribute to observed improvements.
Conclusions:
- Amantadine (Amd) demonstrates potential as a management option for both Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA).
- Further investigation into amantadine's efficacy and safety profile for these conditions is warranted.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...